NCT04661540 - A Study of Auxora in Patients With Critical COVID-19 Pneumonia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

May 9, 2021

Study Completion Date

November 2, 2021

Conditions

Pneumonia

Interventions

DRUG

CM4620-IE (Injectable Emulsion)

Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion

DRUG

Placebo

Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion

Trial Locations (1)

60611

Northwestern Memorial Hospital, Chicago